LYS — Lysogene SA Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Annual income statement for Lysogene SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2017 December 31st | 2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 3.59 | 13.4 | 13.4 | 3.73 |
| Cost of Revenue | |||||
| Gross Profit | -12.5 | -7.18 | -3.21 | -0.332 | -8.98 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 17.2 | 14.5 | 18.5 | 18.4 | 17 |
| Operating Profit | -17.2 | -11 | -5.08 | -5.08 | -13.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -17.8 | -10.9 | -4.28 | -5.09 | -13.6 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -17.8 | -10.9 | -4.28 | -5.09 | -13.6 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -17.8 | -10.9 | -4.28 | -5.09 | -13.6 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -17.8 | -10.9 | -4.28 | -5.09 | -13.6 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.52 | -0.869 | -0.315 | -0.322 | -0.807 |
| Dividends per Share |